Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEUTERON: Pharmacokinetics of High Dose Aflibercept in DME or nAMD
NCT06591598Phase 4Completed
- Sponsor
- Bayer
- Start
- Sep 2024
- Primary completion
- Oct 2025
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 4, open-label trial of aflibercept in diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by Bayer. Primary endpoint: Maximum Observed Concentration of Free Aflibercept. Started Sep 2024; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06591598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06591598.